[ad_1]
Since the introduction of Kavid-19 in Bangladesh, Globe Biotech has been working to develop a vaccine for the disease. And the three vaccines they have developed have been included in the World Health Organization’s list of preclinical vaccine candidates. The World Health Organization (WHO) also said that the landscape document was created to provide information on the new coronavirus epidemic. This list does not imply that a particular product is approved by the World Health Organization.
The World Health Organization overview document lists a total of 42 vaccines on the Clinical Evaluation List and 156 on the Preclinical Evaluation List. Three vaccines developed by Globe Biotech Limited of Bangladesh have been included in the list of preclinical evaluations. These are the DNA plasmid vaccine, the adenovirus type 5 vector, the mRNA encapsulated in variant D614G LNP. They started inventing this vaccine on March 6.
Development of the D614G variant LNP-encapsulated mRNA vaccine is at the forefront, the company said.
How it began?
Since the introduction of Kavid-19 in Bangladesh, Globe Biotech has been working to develop a vaccine for the disease. Globe Biotech scientists discovered a special type of mutation by analyzing genome sequences that existed internationally at the time. This mutation is D614G. The number of mutations was very low at the time, said the CEO of Globe Biotech. Kakon Nag. At that point, he said, they realized that this genome mutation would have dire consequences in the future. So they decided to work on it. He said that at that time no one could have imagined that this strain would dominate the entire world.
According to Globe Biotech, D614G is currently 10 times more contagious than any other strain in the world, and no one has yet developed a candidate vaccine against it.
In what stage?
Among the three vaccine candidates, the most advanced in terms of development is the LNP-based variant D614G-encapsulated mRNA candidate. Basically, your preclinical trial is over. It is currently in the clinical trial phase.
Quality and Regulatory Operations Manager at Globe Biotech. Mohammad Mohiuddin said that the preclinical trial of one of the three candidates for the vaccine has been completed successfully. Preparations for the clinical trial are already underway.
A memorandum of understanding was signed with the ICDDRB on October 14. They will conduct this clinical trial. ICDDRB is currently working on the review of protocol development. Dr. Mohammad Mohiuddin said they have some arrangements of their own that they are working to follow.
Mohiuddin said that the ICDDRB would promptly submit a request in this regard to the Bangladesh Medical Research Council-BMRC. The other two strains are still in the preclinical phase.
What other steps are left?
There are several stages in the development of a vaccine. The LNP variant encapsulated mRNA candidate D614G has already gone through six steps. You are now in the seventh step. This step is the clinical or human trial. Again, there are three steps in this clinical trial. In many places there are four steps. CEO of Globe Biotech. Kakon Nag said that this Total Human Trial is pending.
Apart from this, the vaccine development work has already been completed. Dr. Kakon Nag said it remains to be seen whether the human body will develop a defense against the Kavid-19 virus and whether it has any side effects on the human body.
Nag said the vaccine has already been tested on animals and has shown good and promising results. He also said that as a result of which he will actually go to human judgment. Nag said the current data is very hopeful that it will also work very well in the human body.
When are you coming?
According to Globe Biotech, the clinical trial of the vaccine is expected to be completed within five to six months. But Globe Biotech says management and approval matters are out of their hands.
There are separate authorities for these matters. Globe Biotech officials said the vaccine would be available within six months if approved as soon as possible.
How far will this vaccine go?
Nag said the D614G vaccine is currently in a first-stage clinical trial. Globe Biotech Limited said it plans to go beyond the rest of the steps and make the vaccine available to everyone. The agency says several countries have already expressed interest in testing the vaccine. “Just as Bangladesh is competing for vaccines from China, India or Russia, other countries have also expressed interest in testing our vaccines in their countries,” Nag said.
Noting that no one else has the D614G candidate for the vaccine, he said they hope it is a “superior” vaccine.
What is the difference between the three vaccine candidates?
The so-called Bancovid vaccine, which is being developed by Globe Biotech Limited, has three technical differences between the three candidates. Furthermore, the purpose of the three candidates is to resist Kavid-19. The molecule in this vaccine that will be effective against the virus is the same for all candidates. And that’s the D614G. But the technology to produce these candidates is different. The leading candidate is the D614G variant LNP-encapsulated mRNA, which they claim is the most advanced and safe production technology in the world.
The candidate named Adenovirus Type 5 Vector is close to the technology used by the University of Oxford to develop the vaccine, Nag said. He said another technology was being worked on to make the vaccine cheaper. That is DNA technology. But this technology has not proven to be very safe in the past. Therefore, development work has been postponed.
How will the Bancovid vaccine work?
Said the CEO of Globe Biotech Limited. When Bancovid’s vaccine is applied to the human body, its molecule called mRNA will enter certain cells in the body, Kakon Nag said.
This molecule will be close to the peak protein of the Kavid-19 SARS-Kav-2 virus. This spike protein will then act as an antigen and the antibody will subsequently be produced. Nag said that if you get vaccinated, the body will produce these antibodies and its memory cells and T cells will be produced. As a result, if the person is infected with the SARS-COV-2 virus, these antibodies will be able to detect it and quickly remove it from the body. . He said the virus could no longer infect humans.
[ad_2]
